Mounjaro clocked in Rs 80 crore in sales in September, becoming India's second-highest selling drug within six months of ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.6% in the afternoon session after the stock's positive ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 5.5% in the afternoon session after reports revealed a ...

After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is ...

Eli Lilly’s valuation has compressed significantly from last year’s highs, despite improving fundamentals. See why I rate LLY ...

Eli Lilly’s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside.

LONDON,ENGLAND - MAY 30: A photo illustration of a Mounjaro pen on May 30 2025 in London, England. Mounjaro is a treatment for weight loss and type 2 diabetes. (Photo by Peter Dazeley via Getty Images ...

On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Eli Lilly continues to establish its dominance in the growing market for GLP-1 therapies. The company's oral candidate for ...

The API facility, which will make orforglipron amongst other small molecules, is part of Eli Lilly’s $27bn US manufacturing ...

Lilly has received approval from the US Food and Drug Administration (FDA) for Inluriyo (imlunestrant) to treat advanced ...